London, May 24, 2006 - GE Healthcare Financial Services has provided a £4 million term loan facility to Arrow Therapeutics, a UK privately-held company dedicated to the discovery of novel drugs for anti-infective therapies. Arrow will use the loan proceeds for general working capital, to fund ongoing research and development, and to finance new equipment.

"Arrow is at an exciting stage of development with two significant events expected in the second half of 2006 -- the results of an initial proof of concept study in man for RSV604 (partnered with Novartis); and the planned initiation of Phase I studies for our lead novel NS5a Hepatitis C inhibitor," said Ken Powell, CEO of Arrow. "The GE term loan is ideal for our short-term to medium-term financing needs during a time when our business is progressing rapidly."

"Since its inception, GE's Life Science Finance team has provided flexible financing solutions valued at over $1.2B to over 500 biotech companies across North America - from their first venture round to post-IPO, and we are very pleased to announce this deal as our launch pad into Europe," said Stephan Caron, head of Corporate Finance at GE Healthcare Financial Services in Europe. '"We worked closely with Arrow to understand their needs and evaluate their risk, and quickly design an effective capital solution to meet their short- and long-term business needs."

GE Healthcare Financial Services is a provider of capital, financial solutions, and related services for the global healthcare market. With over $15 billion of capital committed to the healthcare industry, GE Healthcare Financial Services offers a full range of capabilities from equipment financing and real estate financing to working capital lending, vendor programs, and practice acquisition financing. With its knowledge of all aspects of healthcare from hospitals and long-term care facilities to physicians' practices and life sciences, GE Healthcare Financial Services works with customers to create tailored financial solutions that help them improve their productivity and profitability. For more information, visit .

Founded in 1998, Arrow Therapeutics is a privately owned pharmaceutical company based in central London. Arrow's research is focused exclusively on the discovery and development of anti-infective therapeutics and specializes in small molecule drugs with novel mechanisms of action that address the urgent unmet medical needs in the antiviral and antibacterial fields. For more information, visit www.arrowt.co.uk

Media Contacts

Deia Campanelli
GE Healthcare Financial Services
312-441-6169